Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
|Slideshows|October 4, 2018
Let’s Talk About Cognition
Author(s)John J. Campbell, III, MD
Cognitive problems have historically been the last to be recognized and treated in the clinical setting.
Advertisement
View the slides in PDF format. Also see: 7 Components of Depression Evaluation.
Advertisement
Related to this article
Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5